SCHEMBL1852476

SCHEMBL1852476

CN(C)C(=O)c1[c]oc2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.36
SRC P12931 1/20 0.36
ALDH1A1 P00352 6/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 5/20 0.35
HSD17B10 Q99714 2/20 0.35
HPGD P15428 4/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MAPT P10636 1/20 0.34
TP53 P04637 2/20 0.33
NCOA1 Q15788 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
HIF1A Q16665 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PSMB5 P28074 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL638083 0.80 CA12 (0.41) ALDH1A1MEN1KMT2AKDM4ENPC1
SCHEMBL20562769 0.78 KDM4E (0.41) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL6863801 0.77 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL1851860 0.76 KDM4E (0.47) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL11634089 0.70 MAOB (0.49) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL443729 0.68 GAA (0.36) ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL3244642 0.67 MAOB (0.53) ALDH1A1KMT2AKDM4EHSD17B10HPGD
SCHEMBL29581929 0.66 HIF1A (0.56) HIF1A
SCHEMBL221025 0.65 CYP1A2 (0.36) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL1002037 0.65 CA12 (0.36) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA EGFR 2073/4885SRC 594/4885ALDH1A1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.